Fundamental Research Remains a Buy on FinCanna Capital Corp (CALI)

By Austin Angelo

A Wall Street analyst has provided a review for the Financial company yesterday, but retained the same rating on the stock. Fundamental Research’s analyst Siddharth Rajeev reiterates their Buy rating on the shares of FinCanna Capital Corp (CALIResearch Report), with a $0.34 price target.

According to TipRanks.com, Rajeev is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -14.0% and a 25.2% success rate. Rajeev covers the Basic Materials sector, focusing on stocks such as Inception Mining, New Age Metals, and Corvis Gold.

Currently, the analyst consensus on FinCanna Capital Corp is a Moderate Buy with an average price target of C$0.34.

Based on FinCanna Capital Corp’s latest earnings release for the quarter ending July 31, the company reported a quarterly GAAP net loss of C$680K. In comparison, last year the company had a net profit of C$1.28 million.

FinCanna Capital Corp. is currently seeking investment opportunities in the medical cannabis sector in the United States. The company was founded on November 28, 2016 and is headquartered in Vancouver, Canada.

The company’s shares closed last Monday at C$0.12.